Overview: Zika Virus IgM TestIntroduction: The Zika Virus IgM Test detects Zika IgM antibodies to diagnose recent infection, causing fever or rash. Aligned with 2023 CDC guidelines, it uses immunoassays for high specificity, supporting infection screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in immunology for patients with suspected recent Zika virus infection, particularly in endemic areas or during pregnancy.
Other Names: Zika IgM Assay, Zika Acute Infection Test.
FDA Status: Laboratory-developed test (LDT), meeting immunology standards for diagnostic accuracy.
Historical Milestone: Zika IgM testing began in the 2010s during the Zika outbreak in the Americas. Immunoassay methods improved in the late 2010s, enhancing diagnostic precision for arbovirus detection.
Purpose: Detects Zika IgM antibodies to diagnose recent Zika infection, guides treatment, and evaluates patients with fever or rash.
Test Parameters: 1. Zika IgM Antibodies
Pretest Condition: No fasting required. Collect serum, CSF, or saliva. Report history of fever, rash, or travel to Zika-endemic areas.
Specimen: Serum (SST, 2-5 mL), CSF (sterile container, 1-2 mL), Saliva (sterile container, 1-2 mL). Transport in a biohazard container.
Sample Stability at Room Temperature: 8 hours
Sample Stability at Refrigeration: 7 days
Sample Stability at Frozen: 6 months
Medical History: Document fever, rash, joint pain, or history of Zika exposure, including travel history. Include current medications or pregnancy status.
Consent: Written consent required, detailing the tests purpose, Zika infection implications, especially in pregnancy, and risks of sample collection.
Procedural Considerations: Uses enzyme-linked immunosorbent assay (ELISA) to detect Zika IgM antibodies. Results are available in 1-2 days, supporting clinical decisions. Performed in laboratories, often for acute Zika diagnosis in symptomatic patients or pregnant women.
Factors Affecting Result Accuracy: Sample hemolysis or improper storage can affect results. Cross-reactivity with other flaviviruses (e.g., dengue) may reduce specificity.
Clinical Significance: Positive Zika IgM confirms recent infection, guiding supportive care or pregnancy monitoring. Negative results may require PCR or repeat testing to rule out early infection.
Specialist Consultation: Consult an infectious disease specialist or obstetrician for result interpretation, especially in pregnancy.
Additional Supporting Tests: Zika PCR, IgG, or fetal ultrasound to confirm Zika infection and assess complications.
Test Limitations: Non-specific for infection stage; cross-reactivity with flaviviruses possible. Sample quality affects sensitivity.
References: CDC Zika Guidelines, 2023; Clinical Infectious Diseases, Rabe IB, 2022.
